Head-To-Head Review: Xometry (NASDAQ:XMTR) versus Wuhan General Group (OTCMKTS:WUHN)

Xometry (NASDAQ:XMTR) and Wuhan General Group (OTCMKTS:WUHN) are both industrials companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Insider & Institutional Ownership

97.3% of Xometry shares are owned by institutional investors. 9.7% of Xometry shares are owned by insiders. Comparatively, 61.1% of Wuhan General Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Xometry and Wuhan General Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xometry	$686.63 million	3.73	-$61.74 million	($1.22)	-40.49
Wuhan General Group	N/A	N/A	N/A	N/A	N/A

Wuhan General Group has lower revenue, but higher earnings than Xometry.

Risk & Volatility

Xometry has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Wuhan General Group has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Xometry and Wuhan General Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xometry	1	5	5	0	2.36
Wuhan General Group	0	0	0	0	0.00

Xometry currently has a consensus target price of $62.00, suggesting a potential upside of 25.51%. Given Xometry’s stronger consensus rating and higher possible upside, equities analysts clearly believe Xometry is more favorable than Wuhan General Group.

Profitability

This table compares Xometry and Wuhan General Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xometry	-8.99%	-5.49%	-2.24%
Wuhan General Group	N/A	N/A	N/A

Summary

Xometry beats Wuhan General Group on 6 of the 10 factors compared between the two stocks.

About Xometry

Xometry, Inc. operates an online marketplace that enables buyers to source custom-manufactured parts and assemblies in the United States and internationally. It provides computer numerical control manufacturing, sheet metal forming, and sheet cutting; 3D printing, including fused deposition modeling, direct metal laser sintering, PolyJet, stereolithography, selective laser sintering, binder jetting, carbon digital light synthesis, multi jet fusion, and lubricant sublayer photo-curing; and die casting, stamping, injection molding, urethane casting, tube cutting, and tube bending, as well as finishing services, rapid prototyping, and high-volume production services. It serves aerospace, healthcare, robotics, industrial, defense, energy, automotive, government, education, and consumer goods industries. The company was formerly known as NextLine Manufacturing Corp. and changed its name to Xometry, Inc. in June 2015. Xometry, Inc. was incorporated in 2013 and is headquartered in North Bethesda, Maryland.

About Wuhan General Group

Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.